566 results about "Ovarian follicle" patented technology

A method and device for the extraction of follicular units from a donor area on a patient. The method includes scoring the outer skin layers with a sharp punch, and then inserting a blunt punch into the incision to separate the hair follicle from the surrounding tissue and fatty layer. The method and device will significantly decrease the amount of follicular transection and increase the rate at which follicular units can be extracted.

Heterodimeric polypeptide conjugates exhibiting FSH activity, comprising a dimeric polypeptide comprising an FSH-.alpha. subunit and an FSH-.beta. subunit, wherein at least one of the FSH-.alpha. and FSH-.beta. subunits differs from the corresponding wildtype subunit in that at least one amino acid residue acid residue comprising an attachment group for a non-polypeptide moiety has been introduced or removed, and having at least one non-polypeptide moiety bound to an attachment group of at least one of said subunits are provided. Preferably, at least one attachment group, e.g., an N- or O-glycosylation site or an attachment site for a polymer molecule such as polyethylene glycol, has been introduced, e.g., at an N-terminal. The polypeptide conjugates exhibit improved properties, in particular an increased half-life, compared to human FSH.

The present invention discloses a novel method of prevention of birth defects, miscarriages and infertility in women. The two therapies, disclosed herein, the hormone normalization therapy and the aromatase inhibitor-hormone normalization therapy, focus on restoring young hormonal levels in women in order to prevent female infertility and miscarriages, guide follicular and oocyte maturation, and promote correct chromosomal segregation in oocytes and early embryos.

A hair transplantation device can include a generally tubular guide configured to locate a hair follicle bulb by sliding over a hair shaft down to an upper surface of a hair follicle. The guide can have a blunt distal end configured not to transect the hair follicle bulb. The hair transplantation device also includes an outer tubular member sized and configured to be advanced around the guide. The outer tubular member has a dilator and a harvester. The device can be used in a follicle transplantation method in which the guide locates a hair follicle bulb, and the outer tubular member is slid over the guide. Once the outer tubular member is aligned with the guide, the harvesting portion is advanced, cutting dermal tissue surrounding the hair follicle. The outer tubular member is then withdrawn with the hair follicle, relocated in a recipient area, and the hair follicle implanted.

The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.

The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.

This invention relates to sustained release compositions, and methods of forming and using said compositions, in particular for the sustained release of Follicle Stimulating Hormone (FSH). The sustained release compositions comprise a polymeric matrix of a biodegradable biocompatible polymer and stabilized FSH. The method of the invention for forming a sustained release composition includes, dissolving a biodegradable biocompatible polymer in a polymer solvent to form a polymer solution; adding biologically active stabilized FSH; removing the solvent; and solidifying the polymer to form a polymer matrix containing stabilized FSH dispersed therein. Also described is a method for providing a therapeutically effective amount of stabilized FSH in a patient in need of for a sustained period comprising administering to the patient a dose of the sustained release compositions of the invention. The sustained release composition of FSH can be used to promote maturation of follicles, promote spermatogenesis and to treat fertility disorders.

The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.

This invention provides FSH analogues having increased serum half-life relative to FSH. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject.

A method and device for the extraction of follicular units from a donor area on a patient. The method includes aligning a dissecting punch over a follicular unit and rotating the dissecting punch to score the epidermis layer of the skin so that hair follicles are disposed within the lumen. The dissecting punch is then moved through the dermis layer and fatty tissue layer of the skin to dissect the follicular unit from the tissue surrounding the follicular unit.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

This invention provides FSH analogues having increased serum half-life relative to FSH. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject.

The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The recombinant hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G)2 Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.

A method and device for the extraction of follicular units from a donor area on a patient. The method includes aligning a dissecting punch over a follicular unit and rotating the dissecting punch to score the epidermis layer of the skin so that hair follicles are disposed within the lumen. The dissecting punch is then moved through the dermis layer and fatty tissue layer of the skin to dissect the follicular unit from the tissue surrounding the follicular unit.

A punch that is particularly useful for removing curled hair follicles from a donor site comprises a generally tubular body disposed about a generally longitudinal axis and having a distal cutting end region terminating distally in a plurality of distally-extending circumferentially disposed, generally prong-like members carrying distally diverging cutting edges and separated by follicle-accommodating slits. In practice, the punch is oriented during the extraction process at the donor site so that the curled hair root passes into, and is spared from the advancing cutting edge by, a slit as the punch is inserted into and penetrates the tissue. The punch may then rotated slightly so that the cutting edges cut most of the tissue surrounding the follicle without making damaging contact with the follicle. It may be noted that a rotary motion may not be necessary and, if rotation is desired, it may be in one direction or be in the form of an oscillatory rotary movement, depending on characteristics of the donor site and targeted follicle.

A one-time use device to deliver preservative-free follicle stimulating hormone (FSH) solution is disclosed. The device includes a needle covered by a sliding needle shield, which covers the needle in all modes of the device. The device can be placed into a ready-to-use position in four or fewer user steps. The device has a knob for setting a desired dose of FSH. The knob includes longitudinally spaced elements respectively corresponding to the lock position and the seven or fewer discrete dosing positions. The device locks after one use and cannot be reused thereafter.

A device and method for assessing characteristics of follicular fluid in vivo comprises an aspiration needle for oocyte retrieval having one or more sensors disposed on its outer cannula wall or embedded in its outer cannula wall for sensing and measuring characteristics of follicular fluid constituents such as pH level and oxygen concentration. The sensors are microsensors that communicate through a physical connection or wirelessly with a meter and display. The measurements are recorded and optionally printed for later review and selection of the most viable oocytes. The method involves inserting into an ovary an aspiration needle with one or more sensors. The needle is guided to a first follicle and inserted in the first follicle. Characteristics of the follicular fluid are sensed and measured and accordingly displayed on the meter and recorded for later reference and selection. The fluid is collected into a first collection container. The sensors can then be reset to a reference baseline and then additional follicles can be aspirated and measured in the same manner. After collection, the measurements of follicular fluid characteristics for each follicle can be assessed and the most viable oocytes can be selected.

The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G) Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.

The present invention relates to a diagnostic device for measuring the ratio of similar structural proteins among the proteins secreted in a liquid test sample taken from diagnosis subject. In further detail, the test device according to the present invention comprises detection marker-antibody conjugate recognizing the same site on two or more similar structural proteins and a detection zone in which antibody specifically recognizes each of said proteins via formation of sandwich type complex, wherein said antibodies form a set, and the present Invention relates to a diagnostic device for early diagnosis of polycystic ovary syndrome, abnormal pregnancy, prostatic carcinoma etc. based on determination of the ratio of follicle stimulating hormone and luteinizing hormone in case of polycystic ovary syndrome, the ratio between hCG isomers in case of abnormal pregnancy, and the ratio of prostate-specific antigens (PSA) in case of prostatic carcinoma.

The invention relates to the field of hypothermal medicine of biotechnology, in particular to a cryoprotectant free of DMSO (dimethyl sulfoxide). The cryoprotectant comprises 200 mmol / L of trehalose, 0.3 g / mL of PVP (polyvinylpyrrolidone) 40, 200 mu g / L of cholesterol and 200 mu g / L of lecithin. The cryoprotectant is injected into a newly obtained ovary; all macroscopic follicles on the surface of the ovary are punctured and sucked, so that content in the follicles is removed; then the ovary is put in a freezing bag to be cooled. The cryoprotectant doesn't contain DMSO, does not have cytotoxicity and is easy to remove, simple to prepare and good in cryoprotective effect, raw materials are easy to obtained, the rate of normal primordial follicles is high, and the number of dead cells is small; an ovary cryopreservation method is simple and easy to operate and good in cryoprotective effect; the histological structure can be better conserved after the whole ovary of sheep is frozen.

Methods of regulating angiogenesis, ischemic injury and / or wound healing by modulating the activity of leptin, particularly as mediated by the leptin receptor, and / or the interaction between leptin and the leptin receptor. Correspondingly, these methods can also be used to treat diseases mediated by angiogenesis, including wound healing, tumors and tumor metastasis, diabetic microangiopathy, retinal neovascularization, neovascularization of adipose tissue and fat metabolism, revascularization of necrotic tissue, enhancement or vascularization in microvascular transplants, and ovarian follicle maturation. Assays for identifying agents that modulate leptin and / or leptin receptor-mediated angiogenesis and / or wound healing and their use in treating angiogenesis-mediated diseases or conditions involving wound healing are also disclosed.

The invention relates to Chinese herbal medicine feed additive for ewes, which belongs to crashed mixtures and solves the problems that the estrus cycle disorder phenomenon of breeding ewes is more serious, the recessive estrus ratio is high, and the estrus time is dispersive in the prior art. The Chinese herbal medicine feed additive is prepared by crashing and mixing epimedium, motherwort, angelica, Chinese dodder seed, glossy privet fruit, astragalus root and dangshen and can be added into feed for usage. The invention utilizes Chinese herbal medicines to regulate body metabolism functions, has favorable treating effect to uterus inflammations, promotes upgrowth of ovary and uterus, maintains normal estrus cycle, improves symptoms, sexual excitation and upgrowth degree of follicles during ewe estrus, reduces the recessive estrus ratio of ewes, improves follicle quality, shortens estrus duration, forms high-grade corpus luteum, and creates favorable conditions for smooth implantation of fertilization ovum and embryo.

The present invention relates to a system for assessing ovarian reserve functions in subjects. The system for assessing the ovarian reserve functions of the subjects comprises a data acquisition module used for obtaining data of a subject's age, an anti-Mullerian hormone (AMH) level, a follicle stimulating hormone (FSH) level and antral follicle counting (AFC); and a module for calculating the ovarian reserve functions used for calculating information obtained in the data acquisition module to calculate a probability (p) of subject's ovarian hyporesponsiveness. Further, a relationship betweenthe predicted ovarian hyporesponsiveness probability and a medicine dose of an ovulation-promoting medicine is predicted to divide populations into four groups in order to group closes ovarian responsiveness into one group.

Methods and apparatus for interpreting vaginal measurement data by electronic means without the need for the user to take part in the data interpretation process. More specifically, an intelligent probe monitors folliculogenesis and correlates the ovarian function data to probe profile characteristics of the female reproductive cycle. A fertile window is defined with reference to the correlation between folliculogenesis and probe cyclic profiles. Data stored within the apparatus can be downloaded into an external display appliance or data analysis unit. Another aspect of the invention allows for continuous layout of the memory of preceding cycles in the inventory of the apparatus, retaining the most recent while erasing the most distant stored data. These methods assure a reliable fit for the diagnosis of fertility, treatment of infertility as far as timing of treatment procedures, management of subfertility and other gynecological disorders such as luteal phase deficiency or short luteal phase, and the management of premenstrual mood disorders, and of premenopausal and menopausal patients.

The invention relates to the special aquatic product culture technology field, particularly an acrossocheilus fasciatus simulated ecological factory large scale breeding and domestication method. The method comprises the following steps: build an acrossocheilus fasciatus breeding water quality regulation and control pool-build an acrossocheilus fasciatus parent cultivation, oviposition and adult fish domestication pond-build an acrossocheilus fasciatus hatching and fry cultivation culture pond-build an acrossocheilus fasciatus ovarian follicle hatching sieve-make the access to water source-disinfect the acrossocheilus fasciatus parent cultivation, oviposition and adult fish domestication pond-adjust the water level of the acrossocheilus fasciatus parent cultivation, oviposition and adult fish domestication pond-select the parents-oviposition of the parents-ovarian follicle collection-ovarian follicle hatching-fry cultivation-adult fish culture-disease prevention in culture stage. The pure excellent water is used in the whole process. The beneficial effects of the invention are as follows: the sexual gland of the parents grows well because of ecological cultivation; the amount of nature oviposition is huge with big granule and good quality; because of suspension hatching, the outside is dynamic and the inside is static, and the oxygen is enough; the cultivation of the fry in the culture pool is enhanced; the adult fish grows fast because of abundant bait; and similar wild quality is provided because of being similar to nature environment.

The invention discloses a culture method for high-efficiency human follicle stimulating hormone expression CHO cells and belongs to the technical field of bio-pharmaceuticals. According to the culture method, seed cells are prepared into cell suspension, and subculture is performed after resuspension through a serum-free basal culture medium to obtain seed suspension; the obtained seed suspension is inoculated into a bioreactor to be cultured, the serum-free basal culture medium is fed at regular intervals in the culture process, growth situations of the cells are monitored, glucose solution is supplemented, and the cells are harvested after culture. According to the method, the serum-free basal culture medium is used throughout the process, culture in a fermentation tank is performed after reviving and amplification through bottle shaking, the process flow is simple, the cell culture density is high and can be as high as 4*107 / mL , the cell survival rate reaches more than 98%, maintaining time under high density and a high survival rate is long, the yield of end products can reach 40mg / L, and the method is applicable to industrial production.

Methods are provided for activating dormant ovarian primordial follicles in a mammal to promote development to preovulatory follicles.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

The invention provides a beef cattle breeding method. The beef cattle breeding method comprises the following steps that firstly, beef cattle of improved variety are selected; secondly, cows are raised; thirdly, a breeding method is conducted, wherein a, estrus induction is conducted on the cows close to the estrus, the cows are observed very carefully early in the morning and at nightfall, and observation is conducted every 4-5 hours in the daytime for estrus situation identification, and an outer observation method and a rectal palpation method for the follicular development degree are adopted as the estrus situation identification method, and b, artificial fertilization is conducted through a rectum grasping semen deposition method at estrus stage III; fourthly, the cows are kept under the precious care as long as pregnancy is confirmed according to the situation that the cows are not in estrus any longer within two to three months after semen deposition, or through rectum pregnancy check so that the cows can breed healthy calves, and if false pregnancy is found, re-copulation measures are taken in real time to reduce the breeding loss. By means of the method, the physique of the cows is improved, and the breeding rate of the beef cattle is further increased through estrus induction.

The invention relates to a drug for treating polycystic ovarian syndrome. The drug is characterized by comprising an oral medicine and an enema medicine, wherein the oral medicine comprises 15 g of common curculigo rhizome, 10 g of epimedium, 15 g of common cnidium fruit, 15 g of medicinal morinda root, 15 g of dodder, 15 g of glossy privet fruit, 15 g of medlar, 10 g of prepared rhizome of rehmannia, 15 g of angelica, 15 g of szechwan lovage rhizome, 15 g of salvia miltiorrhiza, 15 g of dangshen, 15 g of stir-fried ovate atractylodes root, 15 g of tuckahoe, 30 g of common yam rhizome, 15 g of pinellia, 12 g of seasoned orange peel, and 15 g of officinal magnolia bark, and the enema medicine comprises 15 g of peach seed, 10 g of safflower, 15 g of common burreed tuber, 12 g of cassiabarktree twig, 15 g of trumpetweed, 15 g of speranskia tuberculata, 15 g of common selfheal spike, 15 g of Chinese honeylocust spine, 15 g of szechwan lovage rhizome, 15 g of seaweed, and 15 g of kelp. According to the present invention, treatment philosophy of combination of the oral medicine and the enema medicine is adopted, and blood circulation activating, blood stasis dissipating, swelling subsiding, and stagnation eliminating are adopted to reduce intumescent ovary and thin ovarian follicle, such that ovulation easily occurs.